Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
1.5K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.3K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
1.8K
Skin Cancer01:30

Skin Cancer

6.6K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MetaCAP Diagnosis and Treatment of Gluteal Necrotizing Soft Tissue Infection Caused by Mixed Anaerobic Bacteria Including Prevotella: A Case Report.

International journal of dermatology·2026
Same author

Toward Fair Federated Graph Learning.

IEEE transactions on neural networks and learning systems·2026
Same author

Response to Zhu et al, "Oral JAK inhibitors combined with 308-nm excimer laser in pediatric progressive vitiligo: Further considerations and future directions".

Journal of the American Academy of Dermatology·2026
Same author

Myelin oligodendrocyte glycoprotein antibody-associated disease presenting as encephalitis and concurrent Epstein-Barr virus detection: a case series.

Frontiers in immunology·2026
Same author

[Research progress and clinical practice considerations on assessment tools for gastroesophageal reflux disease in infants and young children].

Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics·2026
Same author

Efgartigimod in myasthenia gravis: Efficacy and steroid-sparing benefits in a real-world cohort.

Clinical neurology and neurosurgery·2026

Related Experiment Video

Updated: Apr 3, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.6K

Temozolomide for Treating Malignant Melanoma.

Rong-Hua Li1, Xiao-Yang Hou1, Chun-Sheng Yang2

  • 1Department of Dermatology, Affiliated Hospital of Xuzhou Medical College, Xuzhou-221002, China.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
|September 17, 2015
PubMed
Summary
This summary is machine-generated.

Temozolomide (TMZ) offers a well-tolerated oral chemotherapy option for metastatic melanoma, improving patient quality of life compared to dacarbazine (DTIC). Further research is needed to enhance TMZ efficacy and overcome resistance in advanced skin cancer.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.2K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Related Experiment Videos

Last Updated: Apr 3, 2026

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.6K
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.2K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Area of Science:

  • Oncology
  • Dermatology
  • Pharmacology

Background:

  • Melanoma is an aggressive skin cancer with increasing prevalence.
  • Advanced metastatic melanoma has a poor prognosis, with limited treatment options.
  • Chemotherapy is the primary palliative treatment for metastatic melanoma.

Purpose of the Study:

  • To compare the efficacy and tolerability of temozolomide (TMZ) versus dacarbazine (DTIC) for metastatic melanoma.
  • To evaluate TMZ's effectiveness in treating brain metastases.
  • To explore TMZ resistance mechanisms and strategies for enhancing its efficacy.

Main Methods:

  • Literature review and comprehensive analysis of relevant studies.
  • Comparison of oral TMZ with intravenous DTIC for palliative treatment.
  • Assessment of treatment-related toxicity and quality of life.

Main Results:

  • Temozolomide (TMZ) is better tolerated than dacarbazine (DTIC), improving patient quality of life.
  • Toxicity profiles of TMZ and DTIC are similar, despite TMZ's higher cost.
  • Chemotherapy, including TMZ and DTIC, plays a palliative role in metastatic melanoma.

Conclusions:

  • Temozolomide (TMZ) presents a viable oral treatment option for metastatic melanoma, enhancing patient well-being.
  • Further research is warranted to address TMZ resistance and optimize its use in advanced melanoma.
  • Comparative analysis provides a reference for future clinical research and treatment strategies.